Vol. 4 No. 9 (2024)
Reimbursement Recommendations

Cariprazine (Vraylar)

decorative image of the issue cover

Published September 3, 2024

Key Messages

  • CADTH recommends that Vraylar should be reimbursed by public drug plans for the treatment of schizophrenia in adults if certain conditions are met.
  • Vraylar should only be covered by public drug plans in a similar manner to other atypical antipsychotic (AAP) drugs for the treatment of adults with schizophrenia.
  • Vraylar should not be reimbursed for use in combination with other AAPs. Also, Vraylar should not be reimbursed for use in patients with treatment-resistant schizophrenia or used as add-on therapy to clozapine. Vraylar should only be reimbursed if the total cost does not exceed the drug program cost of treatment with the least costly reimbursed AAP for the treatment of schizophrenia.